1. DuChemBio IR: What Happened?

DuChemBio will hold an IR session on August 27th focusing on prostate cancer treatment and diagnosis. The IR will cover the current status and future outlook of the prostate cancer treatment market, the importance of diagnostic agents, and DuChemBio’s strategy for entering the theranostics market.

2. Why is DuChemBio Focusing on the Prostate Cancer Market?

The global radiopharmaceutical market is expected to grow at an average annual rate of 10.6%, and the domestic market is also projected to grow by 11.2%. In particular, the launch of Alzheimer’s disease treatments is expected to further accelerate market expansion. Building on its strengths in the existing cancer and brain disease diagnostic markets, DuChemBio aims to secure new growth drivers in the growing prostate cancer market. They are specifically targeting the theranostics market to provide integrated diagnostic and treatment solutions. Increased presence in the Fluvicto-related market is also anticipated.

3. What is DuChemBio’s Future After the IR?

This IR will be an important opportunity to re-evaluate DuChemBio’s corporate value. A successful IR is expected to create momentum for stock price appreciation, driven by expectations for market entry into prostate cancer and Fluvicto-related business. However, if the specific business plan and performance fall short, it could lead to market disappointment. Risk factors such as intensifying competition and exchange rate fluctuations also exist.

4. Action Plan for Investors

  • Carefully review the IR content and evaluate the concreteness and feasibility of DuChemBio’s strategy for entering the prostate cancer market.
  • Analyze DuChemBio’s competitiveness and future growth potential in the theranostics field, and understand the outlook for its Fluvicto-related business.
  • Refer to the financial impact analysis data when making investment decisions.